{
    "nct_id": "NCT02534480",
    "title": "A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Young Volunteers",
    "status": "COMPLETED",
    "last_update_time": "2016-01-12",
    "description_brief": "NGP 555 is a small molecule preventative therapy aimed at reducing Alzheimer's disease amyloid buildup by targeting Abeta 42 production.",
    "description_detailed": "NGP 555 is a gamma-secretase modulator with a selective mechanism to reduce Abeta 42 while raising shorter Abeta forms such as Abeta 37 and 38.\n\nNGP 555 is being developed as a preventative disease modifying therapy for Alzheimer's disease.",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "PREVENTION",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "NGP 555 (NGP-555) \u2014 small-molecule \u03b3\u2011secretase modulator"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The description and clinical reports identify NGP\u2011555 as an orally administered small-molecule \u03b3\u2011secretase modulator developed to shift APP processing so that production of the aggregation-prone A\u03b242 is reduced (with increases in shorter, non-aggregating A\u03b2 species), i.e., a disease\u2011targeting approach aimed at preventing amyloid plaque buildup rather than solely improving symptoms. \ue200cite\ue202turn0search7\ue202turn0search4\ue201.",
        "Act: Key extracted details \u2014 Drug: NGP 555 (aka NGP\u2011555). Drug type / mechanism: small\u2011molecule \u03b3\u2011secretase modulator that lowers A\u03b242 and raises shorter A\u03b2 alloforms (proof of target engagement shown in CSF and preclinical models). Trial details from your title: randomized, placebo\u2011controlled, double\u2011blind, single ascending dose, orally administered in healthy volunteers (placebo used as comparator). \ue200cite\ue202turn0search1\ue202turn0search7\ue201.",
        "Reflect: Classification rationale \u2014 this intervention is a small molecule that directly targets Alzheimer\u2019s amyloid pathology (A\u03b242 production) and therefore fits the definition of a \"disease-targeted small molecule\" rather than a symptomatic cognitive enhancer or a neuropsychiatric treatment. No major ambiguity: sources consistently describe NGP\u2011555 as a \u03b3\u2011secretase modulator developed for disease modification / prevention. \ue200cite\ue202turn0search4\ue202turn0search1\ue201.",
        "Web search results supporting the above (selected sources): 1) Peer\u2011reviewed preclinical/clinical article: NGP 555 described as a \u03b3\u2011secretase modulator that lowers A\u03b242 in CSF and showed proof of target engagement and cognitive benefit in rodent models; full text available on PMC. \ue200cite\ue202turn0search7\ue201. 2) PubMed abstract / clinical summary describing NGP\u2011555 clinical-stage development and its mechanism (shifts production away from A\u03b242). \ue200cite\ue202turn0search4\ue201. 3) Company / press release summarizing Phase 1 trial results (safe, well tolerated; single and multiple ascending dose studies in healthy volunteers; mechanism described as reducing A\u03b242 and increasing shorter A\u03b2 species). \ue200cite\ue202turn0search1\ue201. 4) Product / supplier and summary pages noting NGP\u2011555 bioactivity, brain penetration, and effects on A\u03b2 alloforms in preclinical studies. \ue200cite\ue202turn0search3\ue202turn0search6\ue201."
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The trial drug NGP\u2011555 is described in the record as a small\u2011molecule \u03b3\u2011secretase modulator that shifts APP processing to reduce production of the aggregation\u2011prone A\u03b242 and increase shorter, non\u2011aggregating A\u03b2 species\u2014i.e., it directly targets amyloid beta production and amyloid pathology rather than acting symptomatically. \ue200cite\ue202turn0search1\ue202turn0search2\ue202turn0search4\ue201",
        "Act: Extracted details and mapping to CADRO \u2014 Drug: NGP\u2011555 (NGP 555). Mechanism: \u03b3\u2011secretase modulator (GSM) that lowers A\u03b242 and raises shorter A\u03b2 alloforms (proof of target engagement shown in CSF in human Phase 1 studies and in preclinical models). Trial design: single ascending dose, oral, randomized placebo\u2011controlled in healthy volunteers (safety / PK focus). These details point unambiguously to the Amyloid beta CADRO category because the intervention's primary biological focus is reducing A\u03b242 production and altering A\u03b2 alloform ratios. \ue200cite\ue202turn0search0\ue202turn0search2\ue202turn0search1\ue201",
        "Reflect: The classification 'A) Amyloid beta' aligns with the description and multiple sources: preclinical papers and Phase 1 human biomarker results explicitly report NGP\u2011555 as a \u03b3\u2011secretase modulator that shifts A\u03b2 production away from A\u03b242 toward shorter alloforms (proof of target engagement in CSF), and the stated development goal is prevention/modification of amyloid plaque accumulation. There is no indication the trial is primarily targeting tau, inflammation, synaptic receptors, metabolism, or a non\u2011therapeutic diagnostic aim; therefore 'A) Amyloid beta' is the most specific CADRO match. \ue200cite\ue202turn0search2\ue202turn0search4\ue201",
        "Web search results (selected sources supporting the above): 1) PubMed preclinical study describing NGP\u2011555 as a \u03b3\u2011secretase modulator that lowers A\u03b242 and shows cognitive benefit in rodents. \ue200cite\ue202turn0search1\ue201 2) Human Phase 1 / translational article reporting that NGP\u2011555 produced a beneficial shift in CSF A\u03b237/A\u03b242 and A\u03b238/A\u03b242 ratios and demonstrating proof of target engagement and safety. \ue200cite\ue202turn0search2\ue202turn0search4\ue201 3) Company press release summarizing completion of Phase 1 single and multiple ascending dose studies and describing NGP\u2011555 as an oral GSM that shifts A\u03b2 production away from A\u03b242. \ue200cite\ue202turn0search0\ue201 4) Product/compound summary pages reporting in\u2011vitro and in\u2011vivo lowering of A\u03b242 and favorable PK/brain penetration. \ue200cite\ue202turn0search3\ue201",
        "Output: {\"category\": \"A) Amyloid beta\"}"
    ]
}